DOI: 10.12890/2026_007581
Tertiary hyperparathyroidism in a patient with autosomal dominant pseudohypoparathyroidism type 1b
Authors
vandemergel@hotmail.fr
Keywords
Pseudohypoparathyroidism type 1b (PHP1b), STX16 deletion, tertiary hyperparathyroidism, parathyroid adenomaAbstract
Background: Pseudohypoparathyroidism type 1b (PHP1b) is a rare genetic disorder characterized by renal parathyroid hormone (PTH) resistance. While chronic secondary hyperparathyroidism is common, progression to autonomous tertiary hyperparathyroidism remains exceptionally rare, with only five cases reported in the literature.
Case description: We report the case of a 66-year-old Caucasian woman with an autosomal dominant form of PHP1b (maternal transmission of a STX16 gene deletion) diagnosed at age 35. After 31 years of stable disease managed with calcitriol, she presented with persistent hypercalcemia for 5 years. Longitudinal follow-up revealed a dramatic, tenfold surge in serum intact PTH levels, peaking at 932 ng/l. Physical examination showed a mildly rounded facies and brain imaging revealed basal ganglia calcifications. A neck ultrasound and technetium-99m sestamibi scintigraphy confirmed a right medial parathyroid nodule. The patient underwent surgical resection of the lesion. Histopathology confirmed a follicular parathyroid adenoma. Postoperatively, serum calcium and PTH levels normalized rapidly and remained stable at 6-month follow-up.
Conclusion: Tertiary hyperparathyroidism is a rare but critical long-term complication of PHP1b that typically occurs after decades of stimulation. In patients with PHP1b, the onset of hypercalcemia accompanied by a significant, progressive increase in PTH levels should immediately raise suspicion of an autonomous parathyroid adenoma and prompt targeted imaging and surgical management.
References
- Mantovani G, Bastepe M, Monk D, De Sanctis L, Thiele S, Usardi A, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol. 2018;14(8):476-500. doi: 10.1038/s41574-018-0042-0.
- Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf). 2016;84(6):904-11. doi: 10.1111/cen.12948.
- Nakamura Y, Matsumoto T, Tamakoshi A, Kawamura T, Seino Y, Kasuga M, et al. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol. 2000;10(1):29-33. doi: 10.2188/jea.
- Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS. Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab. 2012;97(9):3025-30. doi: 10.1210/jc.2012-1655.
- Itoh M, Okajima M, Kittaka Y, Yachie A, Wada T, Saikawa Y. Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a. Bone Rep. 2022;16:101569. doi: 10.1016/j.bonr.2022.101569.
- Mazoni L, Apicella M, Saponaro F, Mantovani G, Elli FM, Borsari S, et al. Pseudohypoparathyroidism: Focus on Cerebral and Renal Calcifications. J Clin Endocrinol Metab. 2021;106(8):e3005-e3020. doi: 10.1210/clinem/dgab208.
- Elli FM, Linglart A, Garin I, De Sanctis L, Bordogna P, Srybek V, et al. The Prevalence of GNAS Deficiency-Related Diseases in a Large Cohort of Patients Characterized by the EuroPHP Network. J Clin Endocrinol Metab. 2016;101(10):3657-3668. doi: 10.1210/jc.2015-4310.